Literature DB >> 24051301

The analysis of the human plasma N-glycome in endometriosis patients.

E Berkes1, A Mužinić, J Rigo, H-R Tinneberg, F Oehmke.   

Abstract

OBJECTIVE: Analysis of the plasma N-glycome in endometriosis patients compared with controls. STUDY
DESIGN: In a case-control study, blood samples were collected from patients who underwent either diagnostic or operative laparoscopy between 2008 and 2011 in the Semmelweis University, Budapest, I. Department of Obstetrics and Gynaecology. From these patients, 92 with endometriosis (30 stage I-II and 62 stage III-IV, including altogether 18 deep infiltrating cases) and 62 controls were selected for glycan analysis. After release, plasma N-glycans were subjected to hydrophilic interaction high performance liquid chromatography, which resulted in 19 chromatographic glycan peaks (GP). The abundances of the GPs were compared between the study groups. For statistical analysis a non-parametric test, the Mann-Whitney-U test, was used.
RESULTS: We found a statistically significant decrease of GP1 and increase of GP14, GP17 and GP18 in endometriosis patients. The latter peaks consist of glycans which play a role in inflammatory processes and malignancy. We also found significant differences in GP2, GP4, GP6, and GP9 between controls and the different endometriosis stage groups. The observed alterations in GP2, GP4 and GP6 may be related to altered glycosylation and remodelling of the glycan branches of the IgG molecule. The alterations of GP9 are presumably associated with changes of transferrin glycosylation. Furthermore we detected a highly significant decrease of GP1 in patients with deep infiltrating endometriosis compared with controls.
CONCLUSIONS: This is the first analysis of the plasma N-glycome in endometriosis. The observed changes in GP14, GP17 and GP18 and in GP2, GP4, GP6 and GP9 provide new aspects to the pathophysiology of the disease and the alterations of the GP1 may serve as a new potential marker in the future.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Endometriosis; Glycosylation; N-glycans

Mesh:

Substances:

Year:  2013        PMID: 24051301     DOI: 10.1016/j.ejogrb.2013.08.008

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  6 in total

Review 1.  Blood biomarkers for the non-invasive diagnosis of endometriosis.

Authors:  Vicki Nisenblat; Patrick M M Bossuyt; Rabia Shaikh; Cindy Farquhar; Vanessa Jordan; Carola S Scheffers; Ben Willem J Mol; Neil Johnson; M Louise Hull
Journal:  Cochrane Database Syst Rev       Date:  2016-05-01

2.  Wisteria floribunda agglutinin-binding glycan expression is decreased in endometriomata.

Authors:  Tomoko Hirakawa; Kaei Nasu; Kentaro Kai; Yoko Aoyagi; Terukazu Ishii; Tetsuya Uemura; Mitsutake Yano; Hisashi Narahara
Journal:  Reprod Biol Endocrinol       Date:  2014-10-24       Impact factor: 5.211

3.  Metabolic Profile of Patients with Severe Endometriosis: a Prospective Experimental Study.

Authors:  Federica Murgia; Stefano Angioni; Maurizio Nicola D'Alterio; Silvia Pirarba; Antonio Noto; Maria Laura Santoru; Laura Tronci; Vassilios Fanos; Luigi Atzori; Francesca Congiu
Journal:  Reprod Sci       Date:  2020-11-10       Impact factor: 3.060

4.  Variability of serum IgG sialylation and galactosylation degree in women with advanced endometriosis.

Authors:  Katarzyna Sołkiewicz; Hubert Krotkiewski; Marcin Jędryka; Ewa M Kratz
Journal:  Sci Rep       Date:  2021-03-10       Impact factor: 4.379

5.  The Alterations of Serum IgG Fucosylation as a Potential Additional New Diagnostic Marker in Advanced Endometriosis.

Authors:  Katarzyna Sołkiewicz; Hubert Krotkiewski; Marcin Jędryka; Andrzej Czekański; Ewa Maria Kratz
Journal:  J Inflamm Res       Date:  2022-01-13

Review 6.  Novel diagnostic options for endometriosis - Based on the glycome and microbiome.

Authors:  Zsuzsanna Kovács; Louise Glover; Fiona Reidy; John MacSharry; Radka Saldova
Journal:  J Adv Res       Date:  2021-02-05       Impact factor: 10.479

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.